Cystic fibrosis transmembrane regulator mutation and congenital bilateral absence of the vas deferens A bad combination for successful intracytoplasmic sperm injection outcomes
Reflections on “Association of cystic fibrosis transmembrane-conductance regulator gene mutation with negative outcome of intracytoplasmic sperm injection pregnancy in cases of congenital bilateral absence of vas deferens” by Lu et al.
This document describes the strategy of ovarian tissue cryopreservation to preserve fertility in patients who may undergo gonadotoxic medical therapy, radiation therapy, or gonadectomy.
The 6-month results of the first clinical trial of uterus transplantation are presented. The feasibility of live donor uterus transplantation with a low-dose immunosuppressive protocol is demonstrated.
With the majority of the Patient Protection and Affordable Care Act (ACA) taking effect in 2014, insurers, patients, and healthcare providers in every field of medicine await the law’s full impact.
Professionals involved in patient care need to practice evidence-based medicine and keep in mind, when reading the literature, that proper interpretation is vitally important but not always easy.
We review the recent literature concerning infant, childhood, adolescent, and young adult outcomes after the use of assisted reproductive technology.
Infertility trials should routinely report important maternal, fetal, and neonatal outcomes. These include details regarding pregnancy losses, preterm birth, pre-eclampsia, diabetes, growth restriction, genetic problems, and birth defects.
Outcomes of clinical trials for fertility treatments are often ambiguous and confusing. The preferred outcome in infertility trials is live births per woman (or couple).
Ongoing pregnancy qualifies best as the primary outcome measure of choice in trials in reproductive medicine An opinion paper
Arguments for the use of ongoing pregnancy rate as primary outcome of comparative effectiveness research in reproductive medicine are discussed.
This Views and Reviews explores the many outcomes of clinical trials in infertility that are of interest to clinicians, patients, and public health. It advocates for better tracking of outcomes.